본문 바로가기

A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
RHEUMATOLOGY60(12) · pp.5814 · 2021
피인용
Web of Science 10Scopus 11
FWCI (Scopus)
0.89
JCR IF
JCR 2020 7.58
ISSN
1462-0324

저자

  1. Chang, Sung Hae제1저자Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Div Rheumatol,Coll Med, Cheonan, South Korea
  2. Jun, Jae BumHanyang Univ Hosp Rheumat Dis, Dept Internal Med, Div Rheumatol, Seoul, South Korea
  3. Lee, Yun JongSeoul Natl Univ, Dept Internal Med, Div Rheumatol, Bundang Hosp, Seongnam, South Korea
  4. Kang, Tae YoungYonsei Univ, Dept Internal Med, Div Rheumatol, Wonju Coll Med, Wonju, South Korea
  5. Moon, Ki WonKangwon Natl Univ, Dept Internal Med, Div Rheumatol, Sch Med, Chunchon, South Korea
  6. Ju, Ji HyeonCatholic Univ Korea, Coll Med, Dept Internal Med, Div Rheumatol,Seoul St Marys Hosp, Seoul, South Korea
  7. Kang, Seong WookChungnam Natl Univ, Dept Internal Med, Sch Med, Daejeon, South Korea
  8. Choi, In AhChungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju, South Korea
  9. Park, Yong-BeomYonsei Univ, Dept Internal Med, Div Rheumatol, Wonju Coll Med, Wonju, South Korea
  10. 이승근Pusan Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Busan, South Korea
  11. Lee, Shin-SeokChonnam Natl Univ, Dept Internal Med, Div Rheumatol, Med Sch & Hosp, Gwangju, South Korea
  12. Heo, Nam HunSoonchunhyang Univ, Clin Trial Ctr, Cheonan Hosp, Cheonan, South Korea
  13. Lee, Eun Bong교신저자Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea

초록

© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.Objectives: To assess the efficacy of an endothelin receptor antagonist (ERA) and phosphodiesterase type5 inhibitors (PDE5is) for treating SSc-related digital ulcers (DUs). Methods: This prospective, multicentre, observational cohort study recruited patients with active SSc-related DUs from 13 medical centres in South Korea. The primary outcome was time to cardinal ulcer (CU) healing. A secondary outcome was time to new DU occurrence. Patients were followed up 4, 8, 12 and 24 weeks after treatment initiation. Results: Sixty-three patients were analysed. Their mean age was 49.9 years (s.d. 11.4) and 49 were female. Twenty-eight had limited SSc. Forty-nine patients received ERA, 11 received a PDE5i (9 sildenafil, 1 udenafil and 1 tadalafil) and 3 received other medication. The hazard ratio (HR) for time to CU healing in the ERA group vs the PDE5i group was 0.75 (95% CI 0.35, 1.64; P = 0.47) in an unadjusted model and 0.80 (95% CI 0.36, 1.78; P = 0.59) in a model adjusted for age, sex, use of calcium channel blockers (CCBs), total DU number and initial CU area. The HR for new DU development in the ERA group vs the PDE5i group was 0.39 (95% CI 0.16, 0.93; P = 0.03) in an unadjusted model and 0.32 (95% CI 0.13, 0.81; P = 0.02) in an adjusted model. No patients receiving CCBs developed new DUs at 24 weeks. Conclusion: Time to CU healing is comparable for ERA and PDE5i. ERAs are more effective in reducing new DU occurrence than PDE5is. CCBs may be effective as a background medication.

키워드

clinical trialdigital ulcerobservational cohort studysystemic sclerosistreatmentRAYNAUDS-PHENOMENONDOUBLE-BLINDILOPROSTPREVENTIONSILDENAFILMACITENTANSECONDARYEFFICACYBOSENTAN

식별자

Scopus EID
2-s2.0-85122331565
WoS UID
000746212300051